Loading...

Consun Pharmaceutical Group Limited

1681.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$11.50
HK$0.14(1.23%)

Consun Pharmaceutical Group Limited (1681.HK) Stock Overview

Explore Consun Pharmaceutical Group Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 69.6/100

Key Financials

Market Cap9.8B
P/E Ratio9.90
EPS (TTM)$1.19
ROE0.23%
Fundamental Analysis

AI Price Forecasts

1 Week$12.14
1 Month$10.87
3 Months$10.43
1 Year Target$9.98

1681.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Consun Pharmaceutical Group Limited (1681.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 65.83, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $9.98.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 9.90 and a market capitalization of 9.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

65.83RSI (14)
0.15MACD
32.55ADX
Stats data is not available for 1681.HKStats details for 1681.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 1681.HKAnalyst Recommendations details for 1681.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

CEO

Meng An

Employees

3,164

Headquarters

71, Dongpeng Avenue, Guangzhou

Founded

2013

Frequently Asked Questions

;